Accumulation or retention of free fluid within the peritoneal cavity.
Presence of milky lymph (CHYLE) in the PERITONEAL CAVITY, with or without infection.
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
An operation for the continuous emptying of ascitic fluid into the venous system. Fluid removal is based on intraperitoneal and intrathoracic superior vena cava pressure differentials and is performed via a pressure-sensitive one-way valve connected to a tube traversing the subcutaneous tissue of the chest wall to the neck where it enters the internal jugular vein and terminates in the superior vena cava. It is used in the treatment of intractable ascites.
The serous fluid of ASCITES, the accumulation of fluids in the PERITONEAL CAVITY.
A form of PERITONITIS seen in patients with TUBERCULOSIS, characterized by lesion either as a miliary form or as a pelvic mass on the peritoneal surfaces. Most patients have ASCITES, abdominal swelling, ABDOMINAL PAIN, and other systemic symptoms such as FEVER; WEIGHT LOSS; and ANEMIA.
Tumors or cancer of the PERITONEUM.
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Yoshida sarcoma is a rare and aggressive type of soft tissue cancer, specifically a malignant mesenchymal tumor, which was initially reported in Japan and typically occurs in children and young adults, often associated with a poor prognosis due to its rapid growth and high metastatic potential.
Experimentally induced tumors of the LIVER.
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
A collection of watery fluid in the pleural cavity. (Dorland, 27th ed)
A condition characterized by a dry, waxy type of swelling (EDEMA) with abnormal deposits of MUCOPOLYSACCHARIDES in the SKIN and other tissues. It is caused by a deficiency of THYROID HORMONES. The skin becomes puffy around the eyes and on the cheeks. The face is dull and expressionless with thickened nose and lips.
Functional KIDNEY FAILURE in patients with liver disease, usually LIVER CIRRHOSIS or portal hypertension (HYPERTENSION, PORTAL), and in the absence of intrinsic renal disease or kidney abnormality. It is characterized by intense renal vasculature constriction, reduced renal blood flow, OLIGURIA, and sodium retention.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.
INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.

Identification and characterization of a homozygous deletion found in ovarian ascites by representational difference analysis. (1/991)

We have performed representational difference analysis (RDA) on DNA from tumor cells and normal fibroblasts isolated from the ascites of a patient with ovarian cancer. Five of six products of the RDA were homozygously deleted from the tumor DNA. One of these products has been characterized and identifies a homozygous deletion of approximately 6.9 Mb at chromosome 9p21 in the original ovarian tumor material. This deletion encompasses CDKN2A (p16), CDKN2B (p15), and IFN-alpha. PCR analysis of other tumor cell lines using the novel STS based on the RDA product has shown it to lie between IFN-alpha and p16, and to identify the distal extent of a homozygous deletion in another ovarian cancer cell line. These data provide further evidence for a tumor suppressor locus distinct from, but mapping close to, p16 on 9p21. Cytogenetic analysis using comparative genomic hybridization (CGH) performed on the same primary tumor confirmed a loss of material from chromosome 9p. However, the CGH technique had neither the resolution nor the sensitivity to define a subregion of homozygous loss.  (+info)

Antibiotic penetrance of ascitic fluid in dogs. (2/991)

Antibiotic concentrations in ascitic fluid after parenteral therapy may be important in the treatment of peritonitis. We have created ascites in dogs by partial ligation of the inferior vena cava. Ascitic fluid volume was measured at the time each antibiotic was administered. Nine antibiotics were studied in the same three dogs. Antibiotic concentration in ascitic fluid was found to vary inversely with ascites volume. Percentage of penetration (ratio of ascites peak to serum peak x100) ranged from 5.8 to 65% among the drugs studied. Only metronidazole showed a statistically significant higher percentage of penetration than other antimicrobials. Concentrations in ascitic fluid after single doses of cephalothin (15 mg/kg) and the aminoglycosides (2 mg/kg, gentamicin and tobramycin; 7.5 mg/kg, amikacin and kanamycin) did not exceed the minimum inhibitory concentration of many gram-negative rods and may justify the use of higher than usual initial parenteral doses, or possibly initial intraperitoneal administration in seriously ill patients.  (+info)

An endonuclease from mouse cells specific for single-stranded DNA. (3/991)

An endonuclease with a molecular weight of about 70000 (5-6S) was extensively purified from mouse ascites cells. The enzyme specifically attacks single-stranded DNA which is degraded mainly to oligonucleotides, with 5-10 residues. Supercoiled covalently closed circular phage DNA is converted to the linear relaxed form. The enzyme activity is highly sensitive to salt and can be stimulated by reagents lowering the dielectric constant of the buffer such as dimethylsulfoxide and glycerol.  (+info)

Hyperreactio luteinalis associated with chronic renal failure. (4/991)

Hyperreactio luteinalis is a rare benign condition characterized by bilateral ovarian enlargement associated with pregnancies where high concentrations of maternal serum human chorionic gonadotrophins are present. This condition may mimic the ovarian hyperstimulation syndrome. We report a case of a 34 year old woman with a history of chronic renal failure on haemodialysis who presented at 10 weeks' gestational age with hyperreactio luteinalis which was treated conservatively. Because of chronic renal failure, the presentation and course of the disease was different from that which has been previously reported.  (+info)

Lymph and pulmonary response to isobaric reduction in plasma oncotic pressure in baboons. (5/991)

Plasma colloid osmotic pressure was reduced by 76% (from 19.6 +/- 0.6 to 4.7 +/- 1.5 mm Hg) in five baboons while pulmonary capillary hydrostatic pressure was maintained at a normal level. This resulted in fluid retention, weight gain, peripheral edema and ascites, but no pulmonary edema. Thoracic duct lymph flow increased 6-fold and pulmonary lymph flow 7-fold. Thoracic duct lymph had a lower colloid osmotic pressure (2.0 +/- 0.7 mm Hg) than plasma (4.7 +/- 1.5 mm Hg), whereas the colloid osmotic pressure of pulmonary lymph (4.7 +/- 0.7 mm Hg) was the same as that of plasma. The lymph-plasma ratio for albumin fell in thoracic duct lymph but remained unchanged in pulmonary lymph. The difference between plasma colloid osmotic pressure and pulmonary artery wedge pressure decreased from 15.3 +/- 1.9 to -0.7 +/- 2.9 mm Hg. Despite this increase in filtration force, the lungs were protected from edema formation by a decrease of 11 mm Hg in pulmonary interstitial colloid osmotic pressure and a 7-fold increase in lymph flow.  (+info)

Fas gene mutation in the progression of adult T cell leukemia. (6/991)

Fas antigen (Apo-1/CD95) is an apoptosis-signaling cell surface receptor belonging to the tumor necrosis factor receptor superfamily. Adult T cell leukemia (ATL) cells express Fas antigen and show apoptosis after treatment with an anti-Fas monoclonal antibody. We established the ATL cell line KOB, which showed resistance to Fas-mediated apoptosis, and found that KOB expressed two forms of Fas mRNA, the normal form and a truncated form. The truncated transcript lacked 20 base pairs at exon 9, resulting in a frame shift and the generation of a premature stop codon at amino acid 239. The same mutation was detected in primary ascitic cells and peripheral blood cells. The mutation was not detected in lymph node cells, however, although all of the primary ATL cells were of the same clonal origin. A retroviral-mediated gene transfer of the truncated Fas to Jurkat cells rendered the cells resistant to Fas-mediated apoptosis, suggesting a dominant negative interference mechanism. These results indicate that an ATL subclone acquires a Fas mutation in the lymph nodes, enabling the subclone to escape from apoptosis mediated by the Fas/Fas ligand system and proliferate in the body. Mutation of the Fas gene may be one of the mechanisms underlying the progression of ATL.  (+info)

Effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics and sodium homoeostasis in cirrhotic patients with refractory ascites. (7/991)

Systemic arterial vasodilatation has been implicated in the pathogenesis of sodium retention in cirrhosis. Hydrophobic bile acids, which have vasodilatory actions, may be involved. Ursodeoxycholic acid, a hydrophilic bile acid, could potentially decrease systemic arterial vasodilatation, possibly due to its antioxidant effects, and improve sodium handling in cirrhosis. The effects of ursodeoxycholic acid on systemic, renal and forearm haemodynamics, liver function and renal sodium handling were assessed in vasodilated cirrhotic patients with refractory ascites treated with a transjugular intrahepatic porto-systemic shunt (TIPS). Eight cirrhotic patients with refractory ascites without TIPS placement served as controls for the sodium handling effects of ursodeoxycholic acid. From 1 month post TIPS, seven patients were studied before, after 1 month of treatment with ursodeoxycholic acid (15 and at 1 month follow-up. Lipid peroxidation products were used as indices of its antioxidant effects. Ursodeoxycholic acid caused a significant reduction in sodium excretion in both groups (P<0.05). This, in the post-TIPS patients (urinary sodium excretion: 35+/-8 mmol/day at 1 month versus 93+/-21 mmol/day at baseline, P<0.05), was due to a significant increase in sodium reabsorption proximal to the distal tubule (P<0.05), without any significant changes in systemic, renal or forearm haemodynamics, or in liver function. No significant change in lipid peroxidation products was observed. We conclude that: (i) in cirrhotic patients with refractory ascites, ursodeoxycholic acid causes sodium retention, (ii) the abnormality in sodium handling in the post-TIPS cirrhotic patients appears to be the result of a direct effect on the proximal nephron, suggesting that factors other than systemic vasodilatation also contribute to sodium retention in cirrhosis, (iii) caution should be exercised in administering ursodeoxycholic acid in cirrhotic patients with ascites.  (+info)

Expression of phosphatidylethanolamine N-methyltransferase in Yoshida ascites hepatoma cells and the livers of host rats. (8/991)

Previous studies have implicated phosphatidylethanolamine N-methyltransferase-2 (PEMT2) in the regulation of non-neoplastic liver growth [Tessitore,L., Cui,Z. and Vance,E. (1997) Biochem. J., 322, 151-154]. We have now investigated whether or not PEMT2 is also involved in the control of proliferation of hepatoma cells growing in an animal and cell death by apoptosis in the liver of tumor-bearing rats. PEMT activity was barely detectable and PEMT2 protein was absent in hepatoma cells growing exponentially in vivo whereas CTP:phosphocholine cytidylyltransferase (CT) activity and expression were high. The lack of PEMT2 corresponded with the absence of its mRNA. Both PEMT2 protein and mRNA appeared when cells entered the stationary phase of tumor growth and, in parallel, CT expression decreased. The host liver first became hyperplastic and exhibited a slight increase in CT activity and decrease in PEMT2 expression. During the stationary phase of hepatoma growth the host liver regressed and eventually became hypoplastic following induction of apoptosis. The appearance of apoptosis in the host liver was associated with a marked reduction in both CT activity and expression as well as an enhancement of PEMT activity and PEMT2 expression. McArdle RH7777 hepatoma cells underwent apoptosis when transfected with cDNA for PEMT2. The evidence supports the proposal that PEMT2 may have a role in the regulation of 'in vivo' hepatoma and hepatocyte cell division as well as hepatocyte cell death by apoptosis.  (+info)

Ascites is an abnormal accumulation of fluid in the peritoneal cavity, which is the space between the lining of the abdominal wall and the organs within it. This buildup of fluid can cause the belly to swell and become distended. Ascites can be caused by various medical conditions, including liver cirrhosis, cancer, heart failure, and kidney disease. The accumulation of fluid in the peritoneal cavity can lead to complications such as infection, reduced mobility, and difficulty breathing. Treatment for ascites depends on the underlying cause and may include diuretics, paracentesis (a procedure to remove excess fluid from the abdomen), or treatment of the underlying medical condition.

Chylous ascites is a medical condition characterized by the accumulation of milky, fat-containing fluid in the peritoneal cavity, which is the space within the abdomen that contains the intestines, liver, and other organs. The fluid, called chyle, is normally found in the lymphatic system and is formed when dietary fats are absorbed from the small intestine.

Chylous ascites can occur as a result of damage to the lymphatic vessels that transport chyle from the intestines to the bloodstream. This damage can be caused by various conditions, such as trauma, surgery, tumors, inflammation, or congenital abnormalities. When the lymphatic vessels are damaged, chyle leaks into the peritoneal cavity and accumulates there, leading to ascites.

Symptoms of chylous ascites may include abdominal distension, pain, nausea, vomiting, and weight loss. The condition can be diagnosed through various tests, such as imaging studies or analysis of the fluid in the peritoneal cavity. Treatment typically involves addressing the underlying cause of the condition, as well as managing symptoms and preventing complications. This may include dietary modifications, medications to reduce lymphatic flow, or surgical interventions to repair damaged lymphatic vessels.

I'm sorry for any confusion, but "Carcinoma, Ehrlich Tumor" is not a recognized medical term or a valid medical definition. The term "Ehrlich tumor" is sometimes used to refer to a type of transplantable tumor that was first developed by the German physician Paul Ehrlich in the early 20th century for cancer research purposes. However, it's important to note that this type of tumor is not a naturally occurring cancer and is typically used only in laboratory experiments.

Carcinoma, on the other hand, is a medical term that refers to a type of cancer that starts in cells that line the inner or outer surfaces of organs. Carcinomas can develop in various parts of the body, including the lungs, breasts, colon, and skin.

If you have any specific questions about cancer or a particular medical condition, I would be happy to try to help answer them for you.

A Peritoneovenous Shunt is a medical device used to treat severe ascites, a condition characterized by the accumulation of excess fluid in the abdominal cavity. The shunt consists of a small tube or catheter that is surgically implanted into the abdominal cavity and connected to another tube that is inserted into a vein, usually in the chest or neck.

The shunt works by allowing the excess fluid in the abdomen to flow through the tube and into the bloodstream, where it can be eliminated from the body through the kidneys. This helps to alleviate the symptoms of ascites, such as abdominal pain and swelling, and can improve the patient's quality of life.

Peritoneovenous shunts are typically used in patients who have not responded to other treatments for ascites, such as diuretics or paracentesis (a procedure in which excess fluid is drained from the abdomen using a needle and syringe). While peritoneovenous shunts can be effective in managing ascites, they do carry some risks, including infection, bleeding, and blockage of the shunt. As with any surgical procedure, it's important for patients to discuss the potential benefits and risks with their healthcare provider before deciding whether a peritoneovenous shunt is right for them.

Ascitic fluid is defined as the abnormal accumulation of fluid in the peritoneal cavity, which is the space between the two layers of the peritoneum, a serous membrane that lines the abdominal cavity and covers the abdominal organs. This buildup of fluid, also known as ascites, can be caused by various medical conditions such as liver cirrhosis, cancer, heart failure, or infection. The fluid itself is typically straw-colored and clear, but it may also contain cells, proteins, and other substances depending on the underlying cause. Analysis of ascitic fluid can help doctors diagnose and manage the underlying condition causing the accumulation of fluid.

Tuberculous peritonitis is a specific type of peritonitis (inflammation of the peritoneum, the serous membrane that lines the abdominal cavity and covers the abdominal organs) that is caused by the Mycobacterium tuberculosis bacterium. This form of peritonitis is less common than peritonitis caused by other types of bacteria, but it can occur in people with weakened immune systems or those who have been in close contact with individuals with active TB.

The symptoms of tuberculous peritonitis may include abdominal pain and distension, fever, weight loss, decreased appetite, and ascites (accumulation of fluid in the abdominal cavity). Diagnosis typically involves a combination of clinical evaluation, imaging studies, and laboratory tests, such as cultures or nucleic acid amplification tests (NAATs) to detect the presence of M. tuberculosis in the peritoneal fluid or tissue. Treatment usually involves a prolonged course of multiple antibiotics that are active against M. tuberculosis, along with supportive care to manage any complications or symptoms.

Peritoneal neoplasms refer to tumors or cancerous growths that develop in the peritoneum, which is the thin, transparent membrane that lines the inner wall of the abdomen and covers the organs within it. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant peritoneal neoplasms are often associated with advanced stages of gastrointestinal, ovarian, or uterine cancers and can spread (metastasize) to other parts of the abdomen.

Peritoneal neoplasms can cause various symptoms such as abdominal pain, bloating, nausea, vomiting, loss of appetite, and weight loss. Diagnosis typically involves imaging tests like CT scans or MRIs, followed by a biopsy to confirm the presence of cancerous cells. Treatment options may include surgery, chemotherapy, radiation therapy, or a combination of these approaches, depending on the type, stage, and location of the neoplasm.

Liver cirrhosis is a chronic, progressive disease characterized by the replacement of normal liver tissue with scarred (fibrotic) tissue, leading to loss of function. The scarring is caused by long-term damage from various sources such as hepatitis, alcohol abuse, nonalcoholic fatty liver disease, and other causes. As the disease advances, it can lead to complications like portal hypertension, fluid accumulation in the abdomen (ascites), impaired brain function (hepatic encephalopathy), and increased risk of liver cancer. It is generally irreversible, but early detection and treatment of underlying causes may help slow down its progression.

Ovarian neoplasms refer to abnormal growths or tumors in the ovary, which can be benign (non-cancerous) or malignant (cancerous). These growths can originate from various cell types within the ovary, including epithelial cells, germ cells, and stromal cells. Ovarian neoplasms are often classified based on their cell type of origin, histological features, and potential for invasive or metastatic behavior.

Epithelial ovarian neoplasms are the most common type and can be further categorized into several subtypes, such as serous, mucinous, endometrioid, clear cell, and Brenner tumors. Some of these epithelial tumors have a higher risk of becoming malignant and spreading to other parts of the body.

Germ cell ovarian neoplasms arise from the cells that give rise to eggs (oocytes) and can include teratomas, dysgerminomas, yolk sac tumors, and embryonal carcinomas. Stromal ovarian neoplasms develop from the connective tissue cells supporting the ovary and can include granulosa cell tumors, thecomas, and fibromas.

It is essential to diagnose and treat ovarian neoplasms promptly, as some malignant forms can be aggressive and potentially life-threatening if not managed appropriately. Regular gynecological exams, imaging studies, and tumor marker tests are often used for early detection and monitoring of ovarian neoplasms. Treatment options may include surgery, chemotherapy, or radiation therapy, depending on the type, stage, and patient's overall health condition.

I'm sorry for the confusion, but "Sarcoma, Yoshida" is not a recognized medical term or a specific type of sarcoma in any major oncology reference or database. It appears that "Yoshida" might be referring to a person who described or studied a particular type of sarcoma. However, I cannot find any relevant information related to this exact term.

Sarcomas are cancers that develop from connective tissues such as bones, muscles, tendons, cartilages, nerves, and blood vessels. They can be categorized into two main groups: bone sarcomas and soft tissue sarcomas. There are many subtypes of sarcoma, each with its unique features, diagnostic criteria, and treatment approaches.

If you have more context or information about "Sarcoma, Yoshida," I would be happy to help you further research the topic. However, based on the available data, it is not possible to provide a medical definition for this term.

Experimental liver neoplasms refer to abnormal growths or tumors in the liver that are intentionally created or manipulated in a laboratory setting for the purpose of studying their development, progression, and potential treatment options. These experimental models can be established using various methods such as chemical induction, genetic modification, or transplantation of cancerous cells or tissues. The goal of this research is to advance our understanding of liver cancer biology and develop novel therapies for liver neoplasms in humans. It's important to note that these experiments are conducted under strict ethical guidelines and regulations to minimize harm and ensure the humane treatment of animals involved in such studies.

Portal hypertension is a medical condition characterized by an increased pressure in the portal vein, which is the large blood vessel that carries blood from the intestines, spleen, and pancreas to the liver. Normal portal venous pressure is approximately 5-10 mmHg. Portal hypertension is defined as a portal venous pressure greater than 10 mmHg.

The most common cause of portal hypertension is cirrhosis of the liver, which leads to scarring and narrowing of the small blood vessels in the liver, resulting in increased resistance to blood flow. Other causes include blood clots in the portal vein, inflammation of the liver or bile ducts, and invasive tumors that block the flow of blood through the liver.

Portal hypertension can lead to a number of complications, including the development of abnormal blood vessels (varices) in the esophagus, stomach, and intestines, which are prone to bleeding. Ascites, or the accumulation of fluid in the abdominal cavity, is another common complication of portal hypertension. Other potential complications include encephalopathy, which is a condition characterized by confusion, disorientation, and other neurological symptoms, and an increased risk of bacterial infections.

Treatment of portal hypertension depends on the underlying cause and the severity of the condition. Medications to reduce pressure in the portal vein, such as beta blockers or nitrates, may be used. Endoscopic procedures to band or inject varices can help prevent bleeding. In severe cases, surgery or liver transplantation may be necessary.

Hydrothorax is a medical term that refers to the abnormal accumulation of serous fluid in the pleural space, which is the potential space between the lungs and the chest wall. This condition often results from various underlying pathological processes such as liver cirrhosis, heart failure, or kidney disease, where there is an imbalance in the body's fluid regulation leading to the accumulation of fluid in the pleural cavity. The presence of hydrothorax can cause respiratory distress and other symptoms related to lung function impairment.

Myxedema is not a term used in modern medicine to describe a specific medical condition. However, historically, it was used to refer to the severe form of hypothyroidism, a condition characterized by an underactive thyroid gland that doesn't produce enough thyroid hormones. In hypothyroidism, various body functions slow down, which can lead to symptoms such as fatigue, weight gain, cold intolerance, constipation, and dry skin.

Myxedema specifically refers to the physical signs of severe hypothyroidism, including swelling (edema) and thickening of the skin, particularly around the face, hands, and feet, as well as a puffy appearance of the face. The term myxedema coma was used to describe a rare but life-threatening complication of long-standing, untreated hypothyroidism, characterized by altered mental status, hypothermia, and other systemic manifestations.

Nowadays, healthcare professionals use more precise medical terminology to describe these conditions, such as hypothyroidism or myxedematous edema, rather than the outdated term myxedema.

Hepatorenal syndrome (HRS) is a serious complication that primarily affects people with advanced liver disease, particularly those with cirrhosis. It's characterized by functional renal failure in the absence of structural kidney damage. This means that the kidneys stop working properly, but if they were to be removed and examined, there would be no obvious physical reason for their failure.

The medical definition of hepatorenal syndrome includes specific diagnostic criteria:

1. Presence of liver cirrhosis or fulminant hepatic failure.
2. Evidence of impaired liver function, such as ascites (accumulation of fluid in the abdomen) and elevated levels of bilirubin in the blood.
3. Functional renal failure, defined as a serum creatinine level greater than 1.5 mg/dL or a doubling of the baseline creatinine to a level above 1.5 mg/dL in patients with previously normal renal function.
4. Absence of structural kidney damage, confirmed by a normal urinalysis (no protein or red blood cells in the urine), a high urine sodium concentration (greater than 10 mEq/L), and a low fractional excretion of sodium (less than 1%).
5. No alternative explanation for renal failure, such as sepsis, hypovolemia, or use of nephrotoxic medications.

Hepatorenal syndrome is further divided into two types:

- Type 1 HRS: This form is characterized by a rapid and severe decline in kidney function, with a doubling of the serum creatinine to a level greater than 2.5 mg/dL within two weeks. Type 1 HRS has a poor prognosis, with a median survival time of about two weeks if left untreated.
- Type 2 HRS: This form is characterized by a more gradual and modest decline in kidney function, with a serum creatinine level persistently above 1.5 mg/dL. Type 2 HRS has a better prognosis than type 1, but it still significantly worsens the overall survival of patients with liver cirrhosis.

Hepatorenal syndrome is a serious complication of liver cirrhosis and other forms of advanced liver disease. It requires prompt recognition and treatment to improve outcomes and prevent further deterioration of kidney function.

Experimental neoplasms refer to abnormal growths or tumors that are induced and studied in a controlled laboratory setting, typically in animals or cell cultures. These studies are conducted to understand the fundamental mechanisms of cancer development, progression, and potential treatment strategies. By manipulating various factors such as genetic mutations, environmental exposures, and pharmacological interventions, researchers can gain valuable insights into the complex processes underlying neoplasm formation and identify novel targets for cancer therapy. It is important to note that experimental neoplasms may not always accurately represent human cancers, and further research is needed to translate these findings into clinically relevant applications.

Pleural effusion is a medical condition characterized by the abnormal accumulation of fluid in the pleural space, which is the thin, fluid-filled space that surrounds the lungs and lines the inside of the chest wall. This space typically contains a small amount of fluid to allow for smooth movement of the lungs during breathing. However, when an excessive amount of fluid accumulates, it can cause symptoms such as shortness of breath, coughing, and chest pain.

Pleural effusions can be caused by various underlying medical conditions, including pneumonia, heart failure, cancer, pulmonary embolism, and autoimmune disorders. The fluid that accumulates in the pleural space can be transudative or exudative, depending on the cause of the effusion. Transudative effusions are caused by increased pressure in the blood vessels or decreased protein levels in the blood, while exudative effusions are caused by inflammation, infection, or cancer.

Diagnosis of pleural effusion typically involves a physical examination, chest X-ray, and analysis of the fluid in the pleural space. Treatment depends on the underlying cause of the effusion and may include medications, drainage of the fluid, or surgery.

Peritonitis is a medical condition characterized by inflammation of the peritoneum, which is the serous membrane that lines the inner wall of the abdominal cavity and covers the abdominal organs. The peritoneum has an important role in protecting the abdominal organs and providing a smooth surface for them to move against each other.

Peritonitis can occur as a result of bacterial or fungal infection, chemical irritation, or trauma to the abdomen. The most common cause of peritonitis is a rupture or perforation of an organ in the abdominal cavity, such as the appendix, stomach, or intestines, which allows bacteria from the gut to enter the peritoneal cavity.

Symptoms of peritonitis may include abdominal pain and tenderness, fever, nausea and vomiting, loss of appetite, and decreased bowel movements. In severe cases, peritonitis can lead to sepsis, a life-threatening condition characterized by widespread inflammation throughout the body.

Treatment for peritonitis typically involves antibiotics to treat the infection, as well as surgical intervention to repair any damage to the abdominal organs and remove any infected fluid or tissue from the peritoneal cavity. In some cases, a temporary or permanent drain may be placed in the abdomen to help remove excess fluid and promote healing.

No FAQ available that match "ascites"

No images available that match "ascites"